Screener
Collegium Pharmaceutical, Inc. COLL Segment — Income Tax Expense (Benefit)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Medical expenses | 7,899 | 7,832 | 15,047 | 15,865 |
| Technical operations expenses | 165 | 136 | 415 | 234 |
| Stock-based compensation expense | 14,484 | 10,818 | 25,364 | 22,342 |
| Other segment items(1) | 25,480 | 577 | 31,655 | 2,477 |
| Interest expense | 19,519 | 20,463 | 35,381 | 41,253 |
| Interest income | (2,289) | (2,383) | (5,995) | (4,608) |
| Provision for income taxes | 1,519 | 5,042 | 5,763 | 5,747 |
| Net (loss) income | $(15,051) | $11,983 | $(555) | $14,400 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit)?
- Collegium Pharmaceutical, Inc. (COLL) reported segment — income tax expense (benefit) of $1.52M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit) changed year-over-year?
- Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit) decreased by 69.9% year-over-year, from $5.04M to $1.52M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit)?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit) has grown at a 97.8% compound annual growth rate (CAGR), from -$3.85M to $29.75M.
- What does segment — income tax expense (benefit) mean?
- This metric captures the total provision for income taxes or the benefit recognized by the business segment during the reporting period. It reflects the tax impact of the segment's operational profitability and applicable jurisdictional tax rates. Investors use this to assess the effective tax burden on the segment's pre-tax earnings.
Ask your AI about Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude